Beneficial effect of low ethanol intake on the cardiovascular system: Possible biochemical mechanisms

Vascular Health and Risk Management

Volumn 2, Issue 3, 2006, Pages 263-276

  Vasdev, Sudesh ^a   Gill, Vicki ^a   Singal, Pawan K ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Advanced glycation end products; Biochemical mechanisms; Cardiovascular disease; Hypertension; Low ethanol

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE; ALDEHYDE DEHYDROGENASE; ALPHA TOCOPHEROL; AMINE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; CALCIUM; CYSTEINE; GLUCOSE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LIPOPROTEIN; METFORMIN; METHYLGLYOXAL; PYRIDOXAMINE; PYRIDOXINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; THIAMINE; THIOCTIC ACID; THIOL GROUP; UBIDECARENONE;

ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CYTOSOL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE ADHESION; VASCULAR RESISTANCE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; ETHANOL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; INSULIN RESISTANCE; NAD; OXIDATIVE STRESS;

EID: 33747777128     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.3.263     Document Type: Review

References (148)

1. Alderson NL, Chachich ME, Youssef NN, et al. 2003. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int, 63:2123-33.
2. Alencar JL, Lobysheva I, Geffard M, et al. 2003. Role of s-nitosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone. Mol Pharmac, 63:1148-58.
3. Alexander MC, Lomanto M, Nasrin N, et al. 1988. Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through CIS-acting DNA sequences. Proc Natl Acad Sci U S A, 85:5092-6.
4. Alp NJ, Channon KM. 2004. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol, 24:413-20.
5. Alt N, Carson JA, Alderson NL, et al. 2004. Chemical modification of muscle protein in diabetes. Arch Biochem Biophys, 425:200-6.
6. ε-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest, 104:103-13.
7. Aronson D. 2003. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens, 21:3-12.
8. Aviram M, Rosenblat M, Bisgaier CL, et al. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its function. J Clin Invest, 101:1581-90.
9. Aviram M, Billecke S, Sorenson R, et al. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol, 18:1617-24.
10. Avogaro A, Watanabe RM, Gottardo L, et al. 2002. Glucose tolerance during moderate alcohol intake: Insights on insulin action from glucose/ lactate dynamics. J Clin Endocrinol Metab, 87:1233-8.
11. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes, 52:2110-20.
12. Barrios V, Calderon A, Navarro-Cid J, et al. 2002. N-Acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients. Blood Pressure, 11:235-39.
13. Barter PJ, Nicholls S, Rye KA, et al. 2004. Antiinflammatory properties of HDL. Circ Res, 95:764-72.
14. Baynes JW, Thorpe SR. 2000. Glycoxidation and lipoxidation in atherogenesis. Free Rad Biol Med, 28:1708-16.
15. Beckman JS, Koppenol WH. 1996. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol, 271:C1424-37.
16. Beisswenger PJ, Howell SK, Smith K, et al. 2003. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta, 1637:98-106.
17. Bello AT, Bora NS, Lange LG, et al. 1994. Cardioprotective effects of alcohol: mediation by human vascular alcohol dehydrogenase. Biochem Biophys Res Commun, 203:1858-64.
18. Benedetti A, Comporti M, Esterbauer H. 1980. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta, 620:281-96.
19. Bidasee KR, Nallani K, Yu Y, et al. 2003. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/ calcium-release channels. Diabetes, 52:1825-36.
20. Bonnefont-Rousselot D, Rouscilles A, Bizard C, et al. 2001. Antioxidant effect of ethanol toward in vitro peroxidation of human low-density lipoproteins initiated by oxygen free radicals. Radiat Res, 155:279-87.
21. Boshtam M, Rafiei M, Sadeghi K, et al. 2002. Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitam Nutr Res, 72:309-14.
22. Brooks BR, Klamerth OJ. 1968. Interaction of DNA with bifunctional aldehydes. Euro J. Biochem, 5:178-82.
23. Brown BE, Dean RT, Davies MJ. 2005. Glycation of low-density lipoproteins by methylglyoxal and glycoaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia, 48:361-9.
24. Bushehri N, Jarrell ST, Lieberman S, et al. 1998. Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Geriat Nephrol Urol, 8:95-100.
25. Camargo CA, Hennekens CH, Gaziano JM, et al. 1997. Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med, 157:79-85.
26. Catena C, Novello M, Dotto L, et al. 2003. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens, 21:281-8.
27. Chakravarti RN, Kirshenbaum LA, Singal PK. 1991. Atherosclerosis: Its pathophysiology with special reference to lipid peroxidation. J Appl Cardiol, 6:91-112.
28. Chang KC, Paek KS, Kim HJ, et al. 2002. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol, 61:1184-91.
29. Chang T, Wang R, Wu L. 2005. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med, 38:286-93.
30. Chen P, Tsai A, Wu KK. 1994. Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem, 269:25062-6.
31. Chobanian AV, Alexander RW. 1996. Exacerbation of atherosclerosis by hypertension. Arch Intern Med, 156:1952-6.
32. Cooke CLM, Brockelsby JC, Baker PN, et al. 2003. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Preg, 22:173-84.
33. Corrao G, Bagnardi V, Zambon A, et al. 2004. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prevent Med, 38:613-19.
34. Dargel R. 1992. Lipid peroxidation - a common pathogenetic mechanism? Exp Toxic Pathol, 44:169-81.
35. DeFronzo RA, Ferrannini E. 1991. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension and atherosclerotic cardiovascular disease. Diabetes Care, 14:173-94.
36. Degenhardt TP, Alderson NL, Arrington DD, et al. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic rat. Kidney Int, 61:939-50.
37. De Oliveira e Silva ER, Foster D, McGee Harper M, et al. 2000. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation, 102:2347-52.
38. Ding YA. 1996. Thrombogenic and lipid risk factors in hypertension and coronary artery disease. Jpn Circ J, 60:75-84.
39. Duffy SJ, Gokce N, Holbrook M, et al. 1999. Treatment of hypertension with ascorbic acid. Lancet, 354:2048-9.
40. Ellison RC, Zhang Y, Qureshi MM, et al. 2004. Lifestyle determinants of high-density lipoprotein cholesterol: The National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J, 147:529-35.
41. Facchini F, Chen YDI, Reaven GM. 1994. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care, 17:115-19.
42. Fagrell B, De Faire U, Bondy S, et al. 1999. The effects of light to moderate drinking on cardiovascular diseases. J Intern Med, 246:331-40.
43. Farkas J, Menzel EJ. 1995. Proteins lose their nitric oxide stabilizing function after advanced glycosylation. Biochim Biophys Acta, 1245:305-10.
44. Ferretti G, Bacchetti T, Negre-Salvayre A, et al. 2006. Structural modifications of HDL and functional consequences. Atheroscler, 184:1-7.
45. Ferrannini E, Buzzigoli G, Bonadonna R, et al. 1987. Insulin resistance in essential hypertension. N Engl J Med, 317:350-7.
46. Flack JM, Sowers JR. 1991. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med, 91:11S-21S.
47. Flanagan DEH, Moore VM, Godsland IF, et al. 2000. Alcohol consumption and insulin resistance in young adults. Euro J Clin Invest, 30:297-301.
48. Fodor JG, Frohlich JJ, Genest JJG, et al. 2000. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ, 162:1441-7.
49. Fuh MM, Sheih SM, Wu DA, et al. 1987. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med, 147:1035-8.
50. Furuya DT, Binsack R, Machado UF. 2003. Low ethanol consumption increases insulin sensitivity in Wistar rats. Braz J Med Biol Res, 36:125-30.
51. Genchev GD, Georgieva LM, Weijenberg MP, et al. 2001. Does alcohol protect against ischemic heart disease in Bulgaria? A case-control study of non-fatal myocardial infarction in Sofia. Centr Eur J Public Health, 9:83-6.
52. Haberland ME, Fless GM, Scanu AM, et al. 1992. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem, 267:4143-51.
53. Hangaishi M, Taguchi J, Miyata T, et al. 1998. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Comm, 248:285-92.
54. Hannuksela ML, Rantala M, Kesaniemi YA, et al. 1996. Ethanol-induced redistribution of cholesteryl ester transfer protein (CEPT) between lipoproteins. Atheroscler Thromb Vasc Biol, 16:213-21.
55. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352:1685-95.
56. Hedrick CC, Thorpe SR, Fu MX, et al. 2000. Glycation impairs high-density lipoprotein function. Diabetalogia, 43:312-20.
57. Horiuchi S, Sakamoto Y, Sakai M. 2003. Scavenger receptors for oxidized and glycated proteins. Amino Acids, 25:283-92.
58. Howard G, O'Leary DH, Zaccaro D, et al. 1996. Insulin sensitivity and atherosclerosis. Circulation, 93:1809-17.
59. Jackson R, Stewart A, Beaglehole R, et al. 1985. Alcohol consumption and blood pressure. Am J Epidemiol, 122:1037-44.
60. Kahn NN, Acharya K, Bhattacharya S, et al. 2000. Nitric oxide: The "second messenger" of insulin. IUBMB Life, 49:441-50.
61. Karachalias N, Babaei-Jadidi R, Ahmed N, et al. 2003. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans, 31:1423-5.
62. Kaul M, Siveski-Iiskovic M, Hill M, et al. 1993. Free radicals and the heart. J Pharmacol Toxicol Methods, 30:55-67.
63. Kirstein M, Aston C, Hintz R, et al. 1992. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest, 90:439-46.
64. Kislinger T, Tanji N, Wendt T, et al. 2001. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol, 21:905-10.
65. Klatsky AL, Armstrong MA, Friedman GD. 1990. Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers. Am J Cardiol, 66:1237-42.
66. + channels by ethanol contributes to improved endothelial cell functions. Alcohol Clin Exp Res, 28:1005-11.
67. Kumar KV, Das UN. 1993. Are free radicals involved in the pathobiology of human essential hypertension? Free Rod Res Comm, 19:59-66.
68. Liao Y, Kwan S, Shaughnessy S, et al. 2004. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabet Care, 27:978-83.
69. Lieber CS. 1990. Mechanism of ethanol induced hepatic injury. Pharmac Ther, 46:1-41.
70. Losonczy KG, Harris TB, Havlik RJ. 1996. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr, 64:190-6.
71. Mackness B, Davies GK, Turkie W, et al. 2001. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol, 21:1451-7.
72. Maggi E, Marchesi E, Ravetta V, et al. 1993. Low-density lipoprotein oxidation in essential hypertension. J Hypertens, 11:1103-11.
73. Mancia G, Facchetti R, Bombelli M, et al. 2005. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertens, 45:1072-7.
74. Mayes PA. 1983. Carbohydrate metabolism. In: Martin DW, Rodwell VW, Mayes PA (eds). Harper's Review of Biochemistry 19th ed. Los Altos, CA: Lange Medical Pub. pp 161-87.
75. Merritt R, Guruge BL, Miller DD, et al. 1997. Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model. J Cardiovasc Pharmacol, 30:19-25.
76. Midaoui AE, Elimadi A, Wu L, et al. 2003. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens, 16:173-9.
77. Mitidieri F, de Meis L. 1995. Ethanol has different effects on Ca (2+)-transport ATPases of muscle, brain and blood platelets. Biochem J, 312:733-7.
78. Mizutani K, Ikeda K, Tsuda K, et al. 2002. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens, 20:1607-14.
79. Morcos M, Borcea V, Isermann B, et al. 2001. Effect of α-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diab Res Clin Pract, 52:175-83.
80. Morgan PE, Dean RT, Davies MJ. 2002. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys, 403:259-69.
81. Nagai R, Hayashi CM, Xia L, et al. 2002. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycoaldehyde-modified proteins. J Biol Chem, 277:48905-12.
82. Nagaraj RH, Sarkar P, Mally A, et al. 2002. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys, 402:110-19.
83. Neutel JM. 2000. Why lowering blood pressure is not enough: the hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis, 2:370-4.
84. Okubo Y, Suwazono Y, Kobayashi E, et al. 2001. Alcohol consumption and blood pressure change: 5 year follow-up study of the association in normotensive workers. J Hum Hypertens, 15:367-72.
85. Oshima T, Young EW. 1995. Systemic and cellular calcium metabolism and hypertension. Semin Nephrol, 15:496-503.
86. Oya T, Hattori N, Mizuno Y, et al. 1999. Methylglyoxal modification of protein. J Biol Chem, 274:18492-502.
87. Palinski W, Koschinsky T, Butler SW, et al. 1995. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol, 15:571-82.
88. Park YS, Koh YH, Takahashi M, et al. 2003. Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185. Free Rad Res, 37:205-11.
89. Pepine CJ, Handberg EM. 2001. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. Clin Cardiol, 24:V1-5.
90. Piano MR. 2005. The cardiovascular effects of alcohol: the good and the bad. How low-risk drinking differs from high-risk drinking. AJN, 105:87-91.
91. Pitsavos C, Makrilakis K, Panagiotakos DB, et al 2005. The J-shape effect of alcohol intake on the risk of developing acute coronary syndromes in diabetic subjects: the CARDIO 2000 II Study. Diabet Med, 22:243-8.
92. Portaluppi F, Boari B, Manfredini R. 2004. Oxidative stress in essential hypertension. Curr Pharmaceut Design, 10:1695-8.
93. Rao MN, Marmillot P, Gong M, et al. 2003. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabol, 52:1287-94.
94. Reaven GM. 2003. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrin Metab, 88:2399-403.
95. Resnick LM. 1993. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of "syndrome X". Am J Hyperten, 6:123S-134S.
96. Reynolds K, Lewis LB, Nolen JDL, et al. 2003. Alcohol consumption and risk of stroke. JAMA, 289:579-88.
97. Rodwell VW. 1983. Catabolism of the carbon skeletons of amino acids. In: Martin DW, Rodwell VW, Mayes PA (eds). Harper's Review of Biochemistry 19th ed. Stamford, CO: Appleton & Lange. pp 283-306.
98. Rojas A, Romay S, Gonzalez D, et al. 2000. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res, 86:e50-e54.
99. Ross R. 1999. Atherosclerosis - An inflammatory disease. N Engl J Med, 340:115-26.
100. Saad MF, Rewers M, Selby J, et al. 2004. Insulin resistance and hypertension. The insulin resistance atherosclerosis study. Hypertens, 43:1324-31.
101. Sakaguchi T, Yan SF, Yan SD, et al. 2003. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest, 111:959-72.
102. Scharfstein JS, Keaney JF, Slivka A, et al. 1994. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest, 94:1432-9.
103. Schauenstein E, Esterbauer H, Zollner H. 1977. Aldehydes in biological systems. In: Lagnado JR (ed). Aldehydes in biological systems, their natural occurrence and biological activities. London: Pion Limited. pp 1-7.
104. Schmidt AM, Yan SD, Yan SF, et al. 2001. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest, 108:949-55.
105. II in neonatal mesangial cells. Am J Physiol Renal Physiol, 278:F676-83.
106. Sechi LA, Griffin CA, Giacchetti G, et al. 1996. Abnormalities of insulin receptors in spontaneously hypertensive rats. Hypertens, 27:955-61.
107. Shamsi FA, Partal A, Sady C, et al. 1998. Immunological evidence for methylglyoxal-derived modifications in vivo. J Biol Chem, 273:6928-36.
108. Shinozaki K, Kashiwagi A, Masada M, et al. 2004. Molecular mechanism of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiov Haemat Dis, 4:1-11.
109. Shinozaki K, Suzuki M, Ikebuchi M, et al. 1996. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care, 19:1-7.
110. Sima A, Stancu C. 2002. Modified lipoproteins accumulate in human coronary atheroma. J Cell Mol Med, 6:110-11.
111. Singh RB, Niaz MA, Rastogi SS, et al. 1999. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Human Hypertens, 13:203-8.
112. Smit AJ, Lutgers HL. 2004. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem, 11:2767-84.
113. Stampfer MJ, Hennekens CH, Manson JE, et al. 1993. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med, 328:1444-9.
114. Stephens NG, Parsons A, Schofield PM, et al. 1996. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet, 347:781-6.
115. Stiff AW, Frizzell N, Thorpe SR. 2004. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Design, 10:3349-60.
116. Stocker R, Keaney JF. 2004. Role of oxidative modifications in atherosclerosis. Physiol Rev, 84:1381-478.
117. Sub I, Shaten BJ, Cutler JA, et al. 1992. Alcohol use and mortality from coronary heart disease: The role of high-density lipoprotein cholesterol. Ann Intern Med, 116:881-7.
118. Taddei S, Ghiadoni L, Virdis A, et al. 2003. Mechanisms of endothelial dysfunction: Clinical significance and preventative non-pharmacological therapeutic strategies. Curr Pharmaceut Design, 9:2385-402.
119. Takeuchi M, Yamagishi S. 2004. TAGE (toxic AGEs) hypothesis in various diseases. Med Hypoth, 63:449-52.
120. Tegos TJ, Kalodiki E, Sabetai MM, et al. 2001. The genesis of atherosclerosis and risk factors: A review. Angiology, 52:89-98.
121. Thornalley P, Wolff S, Crabbe J, et al. 1984. The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim Biophys Acta, 797:276-87.
122. Thornalley PJ, Battah S, Ahmed N, et al. 2003. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J, 375:581-92.
123. Thornalley PJ. 1993. The glyoxalase system in health and disease. Mol Aspects Med, 14:287-371.
124. Thorpe SR, Baynes JW. 2003. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids, 25:275-81.
125. Thun MJ, Peto R, Lopez AD, et al. 1997. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med, 337:1705-14.
126. Touyz RM, Schiffrin EL. 2004. Reactive oxygen species in vascular biology: implications for hypertension. Histochem Cell Biol, 122:339-52.
127. Trovati M, Anfossi G, Massucco P, et al. 1997. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes, 46:742-9.
128. Uzun H, Karter Y, Aydin S, et al. 2004. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens, 18:523-8.
129. Vasdev S, Ford CA, Longerich L, et al. 1998. Aldehyde induced hypertension in rats: Prevention by N-acetylcysteine. Artery, 23:10-36.
130. Vasdev S, Ford CA, Longerich L, et al. 1999. Antihypertensive effect of low ethanol intake in spontaneously hypertensive rats. Mol Cell Biochem, 200:85-92.
131. Vasdev S, Ford CA, Parai S, et al. 2000a Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens, 18:567-73.
132. Vasdev S, Ford CA, Parai S, et al. 2000b. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis, 10:339-46.
133. Vasdev S, Gill V, Longerich L. 2005. Role of methylglyoxal in essential hypertension. In: Gupta SK, Singal PK, Agrawal (eds). New Delhi, India: Anamaya Pub. pp 72-88.
134. Vasdev S, Longerich L, Singal P. 2002. Nutrition and hypertension. Nutr Res, 22:111-23.
135. Venkov CD, Myers PR, Tanner MA, et al. 1999. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb Haemost, 81:638-42.
136. Verbeke P, Perichon M, Friguet B, et al. 2000. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells. Biochim Biophys Acta, 1502:481-94.
137. Vlachopoulos C, Tsekoura D, Tsiamis E, et al. 2003. Effect of alcohol on endothelial function in health subjects. Vasc Med, 8:263-5.
138. Vlasakova Z, Pelikanova T, Karasova L, et al. 2004. Insulin secretion, sensitivity, and metabolic profile of young healthy offspring of hypertensive patients. Metab, 53:469-75.
139. Wang X, Desai K, Clausen JT, et al. 2004. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kid Internat, 66:2315-21.
140. Wang Y, Marshall SM, Thompson MG, et al. 2005. Cardiovascular risk in patients with end-stage renal disease: a potential role for advanced glycation end products. Contrib Nephrol, 149:168-74.
141. Wautier MP, Chappey O, Corda S, et al. 2001. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab, 280:E685-94.
142. Witztum JL, Steinberg D. 1991. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 88:1785-92.
143. 2 and generation of arachidonic acid. Circ, 108:1858-64.
144. World Health Organization. 2003a. World Health Report. Chapter 6: Neglected global epidemics: three growing threats [online]. Accessed on 8 February 2006. URL: http://www.who.int/entity/whr/2003/en/Chapter6-en.pdf. pp 1-15.
145. World Health Organization. 2003b. Global strategy on diet, physical activity and health: chronic disease risk factors. Accessed on 8 February 2006. URL: http://www.who.int/dietphysicalactivity/publications/facts/ riskfactors/en/.
146. Wu L, Juurlink BHJ. 2002. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertens, 39:809-14.
147. Yoshida R, Shioji I, Kishida A, et al. 2001. Moderate alcohol consumption reduces urinary 8-hydroxydeoxyguanosine by inducing of uric acid. Indust Health, 39:322-9.
148. 2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem, 264:21725-36.